Pieris Pharmaceuticals stock advances in HER2 gastric cancer pipeline amid phase 2 momentum

Pieris Pharmaceuticals (ISIN: US72016P1057) gains spotlight as Cinrebafusp alfa enters phase 2 for HER2-positive gastric cancer, signaling potential breakthroughs in immunotherapy. German-speaking investors eye biotech opportunities in targeted oncology.

Pieris Pharmaceuticals, a clinical-stage biotech firm, is drawing investor attention with progress in its lead candidate Cinrebafusp alfa (PRS-343), a 4-1BB/HER2 fusion protein now in phase 2 for HER2-expressing solid tumors including gastric cancer. Recent pipeline updates highlight its role in the accelerating HER2-positive gastric cancer landscape, where over 20 companies compete for market entry. For DACH investors, this represents a high-risk, high-reward play in precision oncology, with Europe's strong biotech ecosystem offering partnership potential.

As of: 22.03.2026

By Dr. Elena Voss, Senior Biotech Analyst – Tracking Pieris Pharmaceuticals' Anticalin platform as it targets HER2-driven cancers in a competitive global pipeline race.

Pipeline Momentum in HER2-Positive Gastric Cancer

Cinrebafusp alfa combines 4-1BB-targeting Anticalin proteins with a HER2-targeting antibody, aiming to activate immune responses in HER2-expressing tumors. The drug is in phase 2 development, positioning Pieris among leaders like Jiangsu HengRui Medicine and Daiichi Sankyo in this space. Gastric cancer, particularly HER2-positive forms, remains a high-unmet-need area with limited effective therapies.

Recent reports detail over 20 pipeline drugs, with Pieris' candidate standing out for its bispecific design. This fusion protein seeks to overcome limitations of standalone HER2 antibodies or 4-1BB agonists by co-localizing immune activation at the tumor site. Phase 1 data previously showed tolerability and signals of efficacy, paving the way for expanded trials.

The biotech's Anticalin technology, proprietary protein scaffolds, underpins this approach, offering advantages in stability and specificity over traditional antibodies. Investors monitor upcoming phase 2 readouts, expected to clarify response rates and durability in gastric and other solid tumors.

Phase 2 trials focus on HER2-high gastric cancers, where standard care like trastuzumab yields modest survival benefits. Pieris aims to differentiate through conditional T-cell activation, reducing systemic toxicity. Early combo data with PD-1 inhibitors suggest synergy, a trend across the field.

Competitive Landscape and Recent Trial Activations

The HER2 gastric cancer pipeline surged with recent activations. Seagen's March 17 announcement for DV with tucatinib in solid tumors underscores combo therapy momentum. Daiichi Sankyo's phase 3 triplet on March 16 tests ENHERTU plus chemo and pembro in PD-L1 positive cases.

Pieris' Cinrebafusp alfa fits into mid-stage products, alongside BioInvent's BI-1607 in phase 1/2. Astellas and AstraZeneca also advanced studies in early March, intensifying competition. This cluster of updates signals investor interest in HER2 as a durable target post-breast cancer successes.

Pieris differentiates via its platform's modularity, allowing rapid iteration. While larger players like Roche and Novartis dominate late-stage, Pieris' niche in immune-modulating bispecifics could attract buyout interest. Validation from phase 2 will be pivotal.

Biotech Fundamentals and Financial Position

Pieris, listed on Nasdaq under PIRS (ISIN US72016P1057), focuses exclusively on Anticalin therapeutics. The company has partnerships with major pharma like Servier and AstraZeneca, providing non-dilutive funding. Cash runway extends into 2026, supporting ongoing trials without immediate dilution risk.

Revenue stems from milestones and royalties, with Cinrebafusp alfa as the flagship. Historical phase 1 results in HER2-positive solid tumors showed partial responses, bolstering confidence. The stock trades in USD on Nasdaq, reflecting US-centric investor base but accessible via DACH brokers.

Balance sheet strength allows trial expansion, but biotech volatility persists. No recent price specifics verified across exchanges, but pipeline catalysts drive sentiment. Investors track burn rate and partnership news closely.

Risks and Clinical Hurdles in Oncology Biotech

Phase 2 carries high failure risk, with immune-oncology agents often stumbling on efficacy or safety. Cinrebafusp alfa's 4-1BB component risks liver toxicity, a class effect seen in prior trials. Competitive crowding could limit market share even if successful.

Regulatory paths for gastric cancer combos remain uncertain, with FDA prioritizing breakthroughs. Pieris' small size amplifies funding risks if data disappoints. Patent life on Anticalins provides moat, but generics loom post-2030.

Macro pressures like interest rates squeeze small-cap biotechs, delaying deals. DACH investors must weigh these against upside in a $10B+ HER2 market.

Relevance for DACH Investors

German-speaking investors benefit from EU biotech hubs like Munich and Basel, fostering Pieris partnerships. Roche's HER2 dominance in Switzerland highlights regional expertise. DACH funds hold significant biotech exposure, viewing Pieris as a speculative add-on.

Accessibility via Xetra or regional exchanges simplifies trading. Tax-advantaged wrappers like Depot models suit long-term holds. Currency hedging mitigates USD exposure, with ECB policies aiding stability.

Local media coverage amplifies US catalysts, aiding informed decisions. DACH allocators prioritize pipelines with European trial sites, potentially boosting Pieris appeal.

Strategic Outlook and Partnership Potential

Pieris' platform attracts big pharma, with past deals validating tech. Cinrebafusp success could trigger option exercises or new alliances. Oncology M&A remains robust, offering exit paths.

Expansion to other HER2 indications like breast or lung broadens opportunity. Manufacturing scalability via Anticalins lowers costs versus mAbs. Long-term, royalties provide annuity-like returns.

Investors position ahead of data, balancing risks with sector tailwinds. Pieris exemplifies small-cap biotech's leverage to breakthroughs.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.